Semaglutide

Drug Profile

Semaglutide

Alternative Names: NN-9535; NN-9536; NNC-0113-0217

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Novo Nordisk; Zosano Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 05 May 2017 Novo Nordisk initiates enrolment in the phase III SUSTAIN 9 trial for Type-2 diabetes mellitus (Adjunctive treatment) in Puerto Rico (NCT03086330)
  • 04 May 2017 Novo Nordisk initiates enrolment in the SUSTAIN 10 phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in Finland (EudraCT2016-004965-22)
  • 12 Apr 2017 Novo Nordisk completes a phase II trial in Obesity in Australia, Belgium, Canada, Germany, Israel, Russia, United Kingdom and USA (NCT02453711)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top